WuXi AppTec
company in Philadelphia, United States
Last updated November 4, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
WuXi AppTec is a Shanghai-headquartered contract research, development and manufacturing organization, commonly described as a CRDMO. It provides outsourced scientific and manufacturing services to pharmaceutical, biotechnology and healthcare companies rather than primarily selling medicines under its own consumer-facing product brands. Its platform covers small-molecule drug discovery and development, chemistry manufacturing, biology discovery, preclinical testing, clinical research, analytical and bioanalytical services, pharmaceutical manufacturing, and selected advanced-therapy capabilities. The company operates through a network spanning China, North America and Europe, with additional activities in Singapore and other Asian markets. The company was founded in Shanghai in December 2000 by organic chemist Ge Li and three co-founders. It began as WuXi PharmaTech with a relatively small chemistry laboratory and an emphasis on helping pharmaceutical innovators perform discovery chemistry more efficiently. Its business model was built around an open-access platform: customers could use WuXi's scientists, laboratories, development systems and manufacturing capacity without having to build all of those capabilities internally. The model was intended to reduce development costs, shorten project timelines and allow biotechnology companies to advance candidates through increasingly complex stages of development. WuXi's international profile grew rapidly during the 2000s. It opened chemistry facilities in Tianjin, completed a U.S. initial public offering in 2007 under the symbol WX, and acquired AppTec Laboratory Services in 2008. AppTec added expertise in biologics testing, medical-device testing and related laboratory services, and the combined company adopted the WuXi AppTec name. Subsequent expansion added toxicology, bioanalytical, pharmacokinetic, clinical-research, biologics and commercial-manufacturing capabilities. Acquisitions such as Abgent, MedKey, XenoBiotic Laboratories, Crelux, HD Biosciences and Pharmapace broadened the platform across biology, structure-based drug discovery, bioanalysis, clinical data and biometrics. The company was taken private in 2015 in a transaction reported at approximately $3.3 billion, after which it rebuilt its public-market presence in China. WuXi Biologics was separated and listed in Hong Kong in 2017. WuXi AppTec returned to public markets through a Shanghai listing in 2018 and subsequently completed a Hong Kong listing. This restructuring created a broader WuXi ecosystem while leaving WuXi AppTec focused on chemistry, preclinical, clinical, testing and manufacturing services. During the 2020s, WuXi AppTec invested in new modalities and geographically diversified manufacturing. WuXi STA expanded oligonucleotide and high-potency active-pharmaceutical-ingredient production, while the company acquired a Bristol Myers Squibb drug-product manufacturing site in Couvet, Switzerland, and acquired the United Kingdom cell- and-gene-therapy company OXGENE. It also announced facilities in Middletown, Delaware, and Singapore. Its service portfolio has consequently included small molecules, peptides, oligonucleotides, biologics-related activities, cell and gene therapy support, formulation and drug-product manufacturing, clinical research, and medical-device testing. The company became a major subject of U.S. policy and national-security debate in 2024 and 2025. Members of Congress proposed the BIOSECURE Act, which identified WuXi AppTec and other Chinese biotechnology companies as potential companies of concern for certain U.S. government-related contracts and funding. U.S. officials and media reports raised allegations concerning data security, intellectual property and possible links to Chinese state or military institutions; WuXi AppTec denied unauthorized transfers of client information, denied affiliation with the Chinese Communist Party or People's Liberation Army, and said it complies with applicable law. The company responded with public communications and lobbying efforts in the United States. Those pressures contributed to portfolio changes. WuXi AppTec agreed to sell its U.S. medical-device testing operations to NAMSA, with the transaction completed in February 2025, and sold its WuXi Advanced Therapies and OXGENE operations to Altaris in March 2025. The company said these transactions would sharpen its focus on its core CRDMO platform. As of 2026, WuXi AppTec remains an active, publicly listed global life-science services company. It reports more than 35,000 employees, customers in more than 30 countries and a broad network of laboratories and manufacturing sites. Its stated vision is that every drug can be made and every disease can be treated.
History
WuXi AppTec was established in Shanghai in December 2000 by organic chemist Ge Li and three co-founders. Its original name was WuXi PharmaTech, and its initial activity centered on chemistry services for pharmaceutical research. The founders created the company around an outsourced, open-access model that allowed pharmaceutical and biotechnology customers to use specialized research infrastructure without independently building every laboratory and technical function required for drug discovery. The company expanded its chemistry footprint during the 2000s. It opened facilities in Tianjin and broadened its scientific service offering into bioanalytical work. In 2007, WuXi PharmaTech completed an initial public offering in the United States, with its shares trading on the New York Stock Exchange under the symbol WX. In 2008, it acquired AppTec Laboratory Services, a U.S. company with capabilities in biologics testing, medical-device testing and related laboratory services. The acquisition materially widened WuXi's platform, and the company adopted the WuXi AppTec name. During the early 2010s, WuXi added toxicology, pharmaceutical manufacturing and biologics capabilities. WuXi STA opened a large-scale manufacturing facility in Jinshan in 2010. In 2011, WuXi developed biologics discovery, development and manufacturing operations in Shanghai and Wuxi, acquired MedKey and acquired San Diego-based Abgent. In 2012, the company opened a chemistry facility in Wuhan and a GMP biologics drug-substance facility in Wuxi. It also entered a joint venture with MedImmune, AstraZeneca's biologics arm, to co-develop an anti-IL-6 antibody for the Chinese market. In 2013, WuXi formed a joint venture with PRA International to build a clinical research business in China. In 2014, WuXi opened a biologics biosafety-testing facility in Suzhou and acquired XenoBiotic Laboratories, adding bioanalytical, drug-metabolism and pharmacokinetic services. It also expanded into genomics and bioinformatics through WuXi NextCODE after acquiring NextCODE Health. That business later separated from WuXi AppTec in 2019 and became Genuity Science. A major ownership and capital-markets transition occurred in 2015. WuXi AppTec was taken private in a transaction reported at approximately $3.3 billion, and the company left the U.S. public markets. It subsequently continued expanding internationally. WuXi STA opened a Changzhou campus and operations in San Diego in 2016, while WuXi AppTec acquired German structure-based drug-discovery provider Crelux. In 2017, it acquired HD Biosciences, a biology-focused preclinical drug-discovery CRO. WuXi Biologics was spun off and listed in Hong Kong in 2017. WuXi AppTec itself returned to public markets through a Shanghai IPO in 2018 and later completed a Hong Kong listing. The platform continued to diversify from 2019 onward. WuXi AppTec acquired Pharmapace in 2019, strengthening biometrics and clinical-data capabilities. WuXi STA opened an oligonucleotide active-pharmaceutical-ingredient facility in Changzhou in 2020. In 2021, WuXi acquired OXGENE, a U.K. cell- and gene-therapy research and development company, and acquired a Bristol Myers Squibb drug-product manufacturing facility in Couvet, Switzerland. The company also announced a new campus in Middletown, Delaware. In 2022, it announced a major Singapore expansion and opened a high-potency API facility in Jiangsu. WuXi AppTec's global position became politically contentious in the United States in 2024. Proposed legislation known as the BIOSECURE Act sought to restrict federal contracts and certain federally connected business involving biotechnology companies identified as security concerns, including WuXi AppTec. Congressional letters and media reports raised questions about the company's data handling, intellectual-property controls and possible relationship with Chinese government or military institutions. WuXi denied affiliation with the Chinese Communist Party or People's Liberation Army, rejected allegations of unauthorized data transfers, and emphasized its compliance and information-security procedures. The company also engaged in U.S. advocacy and lobbying in response to the legislative campaign. The regulatory environment contributed to a strategic refocusing. In December 2024, WuXi AppTec announced the sale of WuXi Advanced Therapies and OXGENE to Altaris. The transaction was completed in March 2025. In January 2025, the company announced the sale of its U.S. medical-device testing operations to NAMSA; NAMSA completed the transaction on February 28, 2025. WuXi described both actions as portfolio optimization designed to concentrate resources on its core pharmaceutical CRDMO model. In 2025 and 2026, WuXi AppTec continued reporting growth in its continuing operations while facing increased U.S. scrutiny. The company reported record 2025 performance and highlighted growth in chemistry CRDMO services, peptides, oligonucleotides and late-stage development work. In June 2026, the U.S. Department of Defense placed WuXi AppTec on the Section 1260H list of Chinese military companies operating in the United States. WuXi disputed the designation and filed a federal lawsuit on June 11, 2026. As of August 27, 2026, the company remains active, publicly listed and headquartered in Shanghai, with operations across Asia, Europe and North America.
- 2026
Section 1260H designation challenged
[10]WuXi AppTec challenged the U.S. Department of Defense designation of the company as a Chinese military company in federal court.
- 2025
Divestiture of U.S. medical-device testing operations
[7]WuXi sold its U.S. medical-device testing business to NAMSA, which completed the acquisition on February 28, 2025.
- 2025
Advanced Therapies divestiture completed
[8]Altaris completed its acquisition of WuXi Advanced Therapies and OXGENE on March 7, 2025.
- 2024
Singapore site groundbreaking
[3]WuXi AppTec broke ground on a new Singapore site intended to expand API manufacturing capabilities.
- 2024
BIOSECURE Act controversy
[11]WuXi AppTec became a central target of U.S. legislative and national-security scrutiny concerning Chinese biotechnology companies.
- 2022
Delaware and Singapore expansion plans
[1]The company announced a Middletown, Delaware development site and a major Singapore manufacturing expansion.
- 2021
OXGENE acquisition and Swiss manufacturing expansion
[5]WuXi acquired OXGENE and expanded into large-scale drug-product manufacturing through the Couvet, Switzerland site.
- 2020
Oligonucleotide manufacturing expansion
[1]WuXi STA opened an oligonucleotide API plant in Changzhou.
- 2019
Pharmapace acquisition
[1]The acquisition strengthened biometrics, clinical-data and statistical services.
- 2018
Shanghai and Hong Kong relistings
[1]WuXi AppTec completed a Shanghai IPO and subsequently listed shares in Hong Kong.
Products and positioning
An integrated, open-access global CRDMO platform designed to let pharmaceutical and biotechnology customers outsource discovery, development, testing and manufacturing activities across the drug-development lifecycle.
Small-molecule CRDMO · 2000
WuXi Chemistry
WuXi Chemistry provides discovery chemistry, process research, scale-up, development and commercial manufacturing for small-molecule medicines. Its model links early research with development and manufacturing so that projects can move through the pipeline using a common technical platform. The business also supports newer chemistry modalities such as peptides and oligonucleotides, with capabilities extending from laboratory synthesis to larger-scale production.
Pharmaceutical development and manufacturing · 2010
WuXi STA
WuXi STA is the company's pharmaceutical development and manufacturing business. It supports active pharmaceutical ingredients, drug products, process development, scale-up, technology transfer and commercial supply. Its network includes capabilities for small molecules, peptides, oligonucleotides, high-potency compounds and solid-dose products, with manufacturing sites in China and Europe.
Biology discovery and preclinical research · 2011
WuXi Biology
WuXi Biology provides biology discovery and preclinical services used to identify and characterize drug candidates. Activities include assay development, screening, pharmacology, translational research and related laboratory work. The business grew through internal expansion and acquisitions including Abgent, HD Biosciences and other specialist platforms.
Safety, analytical and bioanalytical testing · 2005
WuXi Testing
WuXi Testing provides toxicology, biosafety, analytical, bioanalytical, drug-metabolism and pharmacokinetic services. The platform supports regulatory submissions and development decisions by generating data on a candidate's identity, purity, exposure, safety and biological behavior. It serves pharmaceutical, biotechnology and selected healthcare customers.
Clinical research and clinical data services · 2013
WuXi Clinical
WuXi Clinical provides clinical research, clinical operations, biometrics, data management and related development services. Its capabilities were expanded through the MedKey joint venture and the Pharmapace acquisition. The business helps customers plan and execute clinical programs and organize the data required for regulatory and development decisions.
Cell and gene therapy services · 2021
WuXi Advanced Therapies
WuXi Advanced Therapies was a contract testing, development and manufacturing platform for cell, gene and other advanced biopharmaceutical therapies. It combined testing, process development, manufacturing and commercialization support, and incorporated OXGENE's technologies for viral-vector and gene-therapy development. WuXi AppTec sold the U.S. and U.K. operations to Altaris in 2025.
Medical-device testing · 2008
Medical-device testing operations
WuXi AppTec's former U.S. medical-device testing operations provided biological safety, microbiology, extractables and leachables and related laboratory services. The facilities in Minnesota and Georgia were sold to NAMSA in 2025, ending WuXi AppTec's direct ownership of those U.S. operations.
Controversies
2026
Section 1260H Chinese military-company designation
The U.S. Department of Defense included WuXi AppTec on its Section 1260H list. WuXi described the designation as incorrect and unsupported, and filed a federal lawsuit seeking to overturn it.
2026
WuXi AppTec discloses cybersecurity incident affecting DEL platform
WuXi AppTec announced on the evening of August 24 that its DNA-encoded library (DEL) platform under its biology business segment had recently suffered a cybersecurity incident. The company activated emergency response procedures, engaged external cybersecurity experts and legal counsel, and said its IT systems were operating normally and the DEL platform's security was under control, with no evidence found that data had been publicly disclosed, misused or improperly exploited. The company contacted affected biology business segment clients and said operations and service capability were unaffected.
2024
U.S. national-security and intellectual-property allegations
WuXi AppTec faced allegations in U.S. political and media discussions that it had relationships with Chinese state or military institutions and that U.S. client intellectual property or data may have been transferred to Chinese authorities without consent. WuXi denied unauthorized transfers, denied affiliation with the Chinese Communist Party or People's Liberation Army, and said it complies with U.S. law.
Marketing campaigns
- 2024U.S. BIOSECURE Act advocacy campaign
United States
After WuXi AppTec was identified in proposed U.S. biotechnology-security legislation, the company launched a public affairs and lobbying response. The campaign emphasized the company's independence from the Chinese Communist Party and People's Liberation Army, its data-security controls and its compliance with U.S. law.
Outcome. The campaign did not prevent continued congressional scrutiny. WuXi later pursued portfolio divestitures and challenged a 2026 Department of Defense designation in court.
- 2020COVID-19 business continuity and collaboration initiative
Global
During the COVID-19 outbreak, WuXi AppTec activated business-continuity measures, worked to protect employees and maintained support for customers' drug-discovery and development programs. The company also participated in international collaboration and hosted COVID-19-related forums.
Outcome. The initiative was presented as a continuity and collaboration effort intended to keep life-science development programs moving during the pandemic.
Brand decisions
2026
Challenge Department of Defense designationOtherBackground
WuXi AppTec disputed its inclusion on the U.S. Department of Defense Section 1260H list.
Action taken
The company filed a complaint in the U.S. District Court for the District of Columbia on June 11, 2026.
Aftermath
The litigation remained an active component of WuXi's response to U.S. national-security restrictions as of August 27, 2026.
2025
Sell U.S. medical-device testing operations to NAMSAM&ABackground
WuXi AppTec described the transaction as portfolio optimization and a way to focus investment on its core pharmaceutical CRDMO platform.
Action taken
The company sold its Minnesota and Georgia medical-device testing facilities to NAMSA; completion occurred on February 28, 2025.
Aftermath
NAMSA integrated the facilities into its medical-device testing network, while WuXi retained its pharmaceutical research, development and manufacturing operations.
2024
Refocus portfolio amid U.S. regulatory pressureStrategyBackground
Proposed U.S. biotechnology-security restrictions increased uncertainty around WuXi's U.S. and European assets and customer relationships.
Action taken
WuXi AppTec agreed to sell WuXi Advanced Therapies and OXGENE to Altaris and later agreed to sell its U.S. medical-device testing operations to NAMSA.
Aftermath
The divestitures reduced exposure to selected non-core activities and concentrated the company more tightly on pharmaceutical CRDMO services.
2021
Acquire OXGENEM&ABackground
WuXi AppTec wanted to strengthen its cell- and gene-therapy platform with scalable viral-vector and gene-engineering technologies.
Action taken
WuXi completed the acquisition of OXGENE, a U.K. contract research and development company, and placed it within WuXi Advanced Therapies.
Aftermath
The acquisition expanded WuXi's European advanced-therapy footprint and added technologies for AAV and lentiviral manufacturing.
2021
Acquire Couvet drug-product manufacturing facilityM&ABackground
WuXi sought European drug-product manufacturing capacity and geographic diversification.
Action taken
WuXi STA acquired a Bristol Myers Squibb manufacturing facility in Couvet, Switzerland.
Aftermath
The site became an important European manufacturing location for drug products and expanded WuXi STA's international supply network.
2018
Return to public marketsOtherBackground
Following the 2015 take-private transaction, WuXi AppTec sought renewed access to public equity capital in China and Hong Kong.
Action taken
The company completed a Shanghai IPO and subsequently listed shares in Hong Kong.
Aftermath
WuXi AppTec became a dual-market listed company and was later included in major Hong Kong market indexes.
IPO proceeds. Private company after 2015 take-private → Shanghai IPO raising more than $900 million, followed by Hong Kong listing (2018)
2017
Spin off WuXi BiologicsStrategyBackground
The biologics business had developed into a substantial standalone platform with its own growth and capital requirements.
Action taken
WuXi Biologics was separated from WuXi AppTec and listed on the Hong Kong Stock Exchange.
Aftermath
The transaction created a separately listed WuXi-related biologics company while WuXi AppTec retained its core chemistry, testing, clinical and manufacturing businesses.
2015
Take-private transactionM&ABackground
WuXi AppTec and other Chinese companies sought valuations closer to their domestic market after trading in the United States.
Action taken
New WuXi Life Science Limited acquired WuXi AppTec in a cash transaction reported at approximately $3.3 billion, and the company was delisted from U.S. exchanges.
Aftermath
The private ownership period preceded the company's return to public markets in Shanghai and Hong Kong in 2018.
Transaction value. Publicly traded on the New York Stock Exchange → Acquired by New WuXi Life Science Limited (2015)
2008
Acquire AppTec Laboratory ServicesM&ABackground
WuXi PharmaTech sought to broaden its chemistry-centered platform with U.S. capabilities in biologics testing, medical-device testing and laboratory services.
Action taken
The company acquired AppTec Laboratory Services and changed its English name to WuXi AppTec.
Aftermath
The transaction created a more comprehensive international research and testing platform.
Recent events
WuXi AppTec raises 2026 full-year guidance[22]
Reported:
WuXi AppTec announced that it had raised its 2026 overall revenue guidance from RMB 58.5–60.5 billion to RMB 61.0–61.9 billion, and its continuing-operations revenue growth guidance from 35–39% to 40–42%.
WuXi AppTec discloses cybersecurity incident affecting DEL platform[21]
Reported:
WuXi AppTec announced on the evening of August 24 that its DNA-encoded library (DEL) platform under its biology business segment had recently suffered a cybersecurity incident. The company activated emergency response procedures, engaged external cybersecurity experts and legal counsel, and said its IT systems were operating normally and the DEL platform's security was under control, with no evidence found that data had been publicly disclosed, misused or improperly exploited. The company contacted affected biology business segment clients and said operations and service capability were unaffected.
Megarobot completes a $65 million funding round[23]
Reported:
Megarobot announced that it had completed a new $65 million funding round led by an unnamed investor, with existing shareholders including WuXi AppTec and others also participating.
WuXi AppTec completes acquisition of OXGENE[24]
Reported:
WuXi AppTec announced that it had completed its acquisition of OXGENE. OXGENE was to become a wholly owned subsidiary of WuXi Advanced Therapies, WuXi AppTec's cell and gene therapy business unit.
Simcha raises $25 million[25]
Reported:
Simcha Therapeutics raised $25 million from WuXi AppTec, Sequoia Capital and Connecticut Innovations to advance its cytokine-engineering work.
WuXi AppTec appoints David Chang to lead WuXi Advanced Therapies[26]
Reported:
WuXi AppTec announced the appointment of Dr. David Chang as Chief Executive Officer of its WuXi Advanced Therapies business unit.
- Unconfirmed
Canbridge Pharmaceuticals completes US$98 million Series D financing[27]
Reported:
Canbridge Pharmaceuticals announced that it had completed a US$98 million Series D financing. General Atlantic and WuXi AppTec led the round, and each had the right to make an additional investment of up to US$10 million subject to agreed conditions.
WuXi AppTec receives 2019 Frost & Sullivan award[28]
Reported:
WuXi AppTec announced that it received Frost & Sullivan’s 2019 Global Integrated Drug Development Competitive Strategy Innovation & Leadership Award.
Sources33 sources
- 1WuXi AppTecen.wikipedia.org
- 2About WuXi AppTecwuxiapptec.com
- 3WuXi AppTec History and Milestoneswuxiapptec.com
- 4WuXi AppTec Leadershipwuxiapptec.com
- 5WuXi AppTec completes acquisition of OXGENEwuxiapptec.com
- 6WuXi AppTec agrees to sell U.S. medical-device testing operations to NAMSAwuxiapptec.com
- 7NAMSA completes acquisition of WuXi AppTec U.S. medical-device testing businessnamsa.com
- 8Altaris completes acquisition of WuXi Advanced Therapies and OXGENEminaris.com
- 9WuXi AppTec 2025 performance announcementwuxiapptec.com
- 10WuXi AppTec legal challenge to Section 1260H designationwuxiapptec.com
- 11Reuters report on U.S. client data allegationsinvesting.com
- 12U.S. Department of Defense Section 1260H informationbusiness.defense.gov
- 13WuXi AppTec | Leading Global CRDMOwuxiapptec.com
- 14WuXi AppTec Delivers Strong H1 2026 Results | WuXi AppTecwuxiapptec.com
- 15About WuXi AppTec | Company Overview & Corporate Informationwuxiapptec.com
- 16Drug Discovery, Development & Manufacturing Services | WuXi AppTecwuxiapptec.com
- 17WuXi AppTec (United States)wikidata.org
- 18COVID-19 business continuity and collaboration initiativeprnewswire.com
- 19U.S. BIOSECURE Act advocacy campaignselectcommitteeontheccp.house.gov
- 20Refocus portfolio amid U.S. regulatory pressurewuxiapptec.com
- 21WuXi AppTec discloses cybersecurity incident affecting DEL platform163.com
- 22药明康德上调2026年全年业绩指引prnasia.com
- 23镁伽完成6500万美元融资news.pedaily.cn
- 24药明康德完成对OXGENE的收购prnewswire.com
- 25Simcha获得2500万美元融资fiercebiotech.com
- 26药明康德任命张博士担任先进疗法业务部门首席执行官prnewswire.com
- 27北海康成完成9800万美元D轮融资finance.sina.com.cn
- 28药明康德获得 2019 年 Frost & Sullivan 奖项prnewswire.com
- 29北海康成完成9800万美元D轮融资，泛大西洋投资集团和药明康德领投tech.sina.com.cn
- 30公司信息更新报告：订单快速增长，小分子持续高增，再次上调全年指引data.eastmoney.com
- 31连续上调指引，药明康德再次惊艳CXO-钛媒体官方网站tmtpost.com
- 32药明康德任命张幼翔博士为高端治疗事业部首席执行官finance.sina.com.cn
- 33药明康德宣布完成对OXGENE的收购，持续加强细胞和基因疗法全球服务能力prnasia.com
Cite this profile: Cite the canonical profile. /brand-wiki/wuxi-apptec · Editorial policy · How profiles are compiled